# The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris

> **NCT06415227** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 55 (estimated)

## Conditions studied

- Vasospastic Angina

## Interventions

- **DRUG:** Vericiguat

## Key facts

- **NCT ID:** NCT06415227
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06415227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06415227, "The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06415227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*